Phaseline

Targets › WT1

WT1 (Wilms tumor protein): drug programs, companies and trials

6 programs from 6 companies in 7 trials: 6 Phase 1, 1 Phase 3; Oncology; next expected readout Nov 2026.

Transcription factor that plays an important role in cellular development and cell survival. Recognizes and binds to the DNA sequence 5'-GCG(T/G)GGGCG-3'. Regulates the expression of numerous target genes, including EPO. Plays an essential role for development of the urogenital system. (UniProt, P19544)

Open in Phaseline: the race on WT1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Sellas Life Sciences GroupGalinpepimut-S
Wilms tumor protein vaccine antigen
WT1Phase 3Acute Myeloid LeukemiaDec 2026
Catherine BollardTumor associated antigen lymphocytes (TAA-T)
Multi-antigen specific cytotoxic T lymphocytes targeting WT1, PRAME, and SURVIVIN
WT1, PRAME, SURVIVINPhase 1Relapsed/Refractory Hematopoietic Malignancies, Acute Myeloid Leukemia and MDS; Brain TumorNov 2026
David Reardon, MDCUE-102
WT1-pHLA-IL2-Fc fusion protein; immuno-oncology therapeutic presenting WT1-derived peptide
WT1Phase 1Recurrent GlioblastomaJan 2027
University Hospital, AntwerpWT1/DC vaccine
Dendritic cell vaccination with WT1 tumor antigen
WT1Phase 1Malignant Pleural MesotheliomaOct 2027
Inovio PharmaceuticalsINO-5401
DNA plasmid encoding WT1, PSMA, and hTERT tumor-associated antigens
WT1, PSMA, HGNCPhase 1GlioblastomaDec 2027
Fred Hutchinson Cancer CenterAutologous HLA-A*02:01-restricted CD4+/CD8+ Anti-WT1 TCR/CD8ab-expressing T-cell
WT1-specific TCR-engineered T cell therapy
WT1Phase 1Acute Myeloid LeukemiaJul 2030

Conditions

Acute Myeloid Leukemia (2) Recurrent Glioblastoma (1) Malignant Pleural Mesothelioma (1) Relapsed/Refractory Hematopoietic Malignancies, Acute Myeloid Leukemia and MDS (1) Brain Tumor (1) Glioblastoma (1)

Modalities

mixed (4), protein or peptide (2)

Companies

Fred Hutchinson Cancer Center (1) David Reardon, MD (1) University Hospital, Antwerp (1) Catherine Bollard (1) Inovio Pharmaceuticals (1) Sellas Life Sciences Group (1)

Related targets

PRAME (1) SURVIVIN (1) PSMA (1) HGNC (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.